Compare MAIN & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MAIN | ICUI |
|---|---|---|
| Founded | 2007 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 4.0B |
| IPO Year | 2014 | 1995 |
| Metric | MAIN | ICUI |
|---|---|---|
| Price | $53.52 | $163.13 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 8 |
| Target Price | $59.86 | ★ $193.38 |
| AVG Volume (30 Days) | ★ 442.9K | 224.5K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | ★ 8.07% | N/A |
| EPS Growth | N/A | ★ 100.62 |
| EPS | 0.93 | ★ 1.96 |
| Revenue | N/A | ★ $2,231,262,000.00 |
| Revenue This Year | $3.68 | N/A |
| Revenue Next Year | $6.91 | $4.44 |
| P/E Ratio | ★ $58.43 | $85.38 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $48.95 | $113.37 |
| 52 Week High | $65.23 | $192.85 |
| Indicator | MAIN | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 38.73 | 51.35 |
| Support Level | $52.80 | $152.46 |
| Resistance Level | $57.95 | $167.67 |
| Average True Range (ATR) | 0.95 | 4.12 |
| MACD | -0.05 | 0.94 |
| Stochastic Oscillator | 10.99 | 68.83 |
Main Street Capital Corp is a principal investment firm focused on providing customized long-term debt and equity capital solutions to lower middle market ("LMM") companies and debt capital to private ("Private Loan") companies owned by or in the process of being acquired by a private equity fund. The group invests principally in secured debt investments, equity investments, warrants, and other securities of LMM companies, typically based in the U.S. The company operates as a single segment with a principal investment objective to maximize total return by generating current income from debt investments and current income and capital appreciation from equity and equity-related investments.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.